Premium
Transforming growth factor‐β1 is a potent inducer of plasminogen activator inhibitor type‐1 in human glioblastoma and carcinoma cell lines
Author(s) -
Helseth Eirik,
Dalen Are,
Unsgaard Geirmund,
Skandsen Toril,
GrØNdahlHansen Jan,
Lund Leif R.
Publication year - 1988
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1699-0463.1988.tb00952.x
Subject(s) - plasminogen activator , urokinase , cancer research , cell culture , inducer , activator (genetics) , carcinoma , transforming growth factor , glioblastoma , biology , chemistry , medicine , endocrinology , biochemistry , gene , genetics
Transforming growth factor‐β1 has been shown to suppress the urokinase activity in the glioblastoma cell line T‐MG1 and the carcinoma cell line T‐CAR1. The molecular mechanisms behind the decrease in the proteolyic activity is shown to be at least partly due to increased synthesis of plasminogen activator inhibitor type‐1 and not by decreased synthesis of urokinase.